清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Comparing Anti–Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin

部分凝血活酶时间 医学 肝素 内科学 凝结
作者
Rebekah A. Wahking,Rachel H. Hargreaves,Sean M. Lockwood,Sabrina K. Haskell,Kelly W. Davis
出处
期刊:Annals of Pharmacotherapy [SAGE]
卷期号:53 (8): 801-805 被引量:6
标识
DOI:10.1177/1060028019835202
摘要

Background: Lab tests such as activated partial thromboplastin time (aPTT) or anti–factor Xa (anti-Xa) levels are typically used to monitor intravenous unfractionated heparin (IV heparin), with recent evidence suggesting that anti-Xa levels may provide a more accurate measure of anticoagulation. Objective: The Lexington Veterans Affairs Health Care System transitioned from using aPTT to anti-Xa levels in January 2017. This study was conducted to evaluate the efficacy and safety of this change. Methods: This was a retrospective cohort study comparing all patients receiving IV heparin per protocol for at least 24 hours from August 1, 2016, to January 31, 2017 (aPTT group), and February 1, 2017, to July 31, 2017 (anti-Xa group). The primary objective was a comparison of IV heparin doses required to achieve goal range between the 2 cohorts. Secondary objectives included a comparison of time to therapeutic goal, percentage of time within goal range, number of rate changes until therapeutic goal, and adverse outcomes, such as number of bleeds. Results: A total of 155 patients were included in this study. Significantly higher IV heparin doses were required to achieve therapeutic goal in the anti-Xa group, despite significantly fewer IV heparin rate changes required. Anti-Xa monitoring was not associated with an increased risk of adverse events. Conclusion and Relevance: Significantly higher IV heparin doses were required to achieve therapeutic anti-Xa levels after transitioning from an aPTT-based protocol in the largely unstudied veteran population. However, the transition from aPTT to anti-Xa monitoring appears safe and efficacious in these patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
12秒前
27秒前
1分钟前
1分钟前
1分钟前
陈无敌完成签到 ,获得积分10
1分钟前
1分钟前
2分钟前
刘贤华完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
3分钟前
offshore完成签到 ,获得积分10
3分钟前
3分钟前
3分钟前
3分钟前
绥生完成签到 ,获得积分10
4分钟前
4分钟前
鹤鸣发布了新的文献求助10
4分钟前
5分钟前
6分钟前
勤奋流沙完成签到 ,获得积分10
6分钟前
6分钟前
Sunny完成签到 ,获得积分10
7分钟前
7分钟前
7分钟前
俊逸吐司完成签到 ,获得积分10
7分钟前
liao完成签到,获得积分10
7分钟前
貔貅完成签到 ,获得积分10
7分钟前
舒服的幼荷完成签到,获得积分10
8分钟前
9分钟前
9分钟前
hiiiiiii发布了新的文献求助10
9分钟前
9分钟前
10分钟前
顾矜应助llllly采纳,获得10
10分钟前
hiiiiiii完成签到 ,获得积分10
10分钟前
11分钟前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3162343
求助须知:如何正确求助?哪些是违规求助? 2813330
关于积分的说明 7899736
捐赠科研通 2472848
什么是DOI,文献DOI怎么找? 1316533
科研通“疑难数据库(出版商)”最低求助积分说明 631375
版权声明 602142